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Abstract
The TGF-b superfamily cytokine MIC-1/GDF15 circulates in all humans and when overproduced in cancer leads to anorexia/
cachexia, by direct action on brain feeding centres. In these studies we have examined the role of physiologically relevant
levels of MIC-1/GDF15 in the regulation of appetite, body weight and basal metabolic rate. MIC-1/GDF15 gene knockout
mice (MIC-12/2) weighed more and had increased adiposity, which was associated with increased spontaneous food intake.
Female MIC-12/2 mice exhibited some additional alterations in reduced basal energy expenditure and physical activity,
possibly owing to the associated decrease in total lean mass. Further, infusion of human recombinant MIC-1/GDF15
sufficient to raise serum levels in MIC-12/2 mice to within the normal human range reduced body weight and food intake.
Taken together, our findings suggest that MIC-1/GDF15 is involved in the physiological regulation of appetite and energy
storage.
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Introduction
The regulation of food intake, energy storage and energy
expenditure are tightly controlled by complex homeostatic
mechanisms. These involve conveying information about total
body nutritional and energy status, as well as the presence of
nutrients in the gut lumen and the circulation, to the central
nervous system (CNS), notably via the release of hormones from
the gut and adipose tissue. The CNS, in turn, initiates the
transcription and release of neuropeptides in the hypothalamus
and brainstem, which then modulate feeding and metabolism in
order to maintain energy homeostasis [1–3]. Gut and adipose
tissue-derived hormones may increase or decrease appetite. Satiety
inducing gut hormones are released in response to food intake, and
mediate rapid regulation of appetite [4], whilst insulin from the
pancreas, and leptin, the circulating levels of which increase with
increasing fat mass, are involved in long-term regulation of energy
balance [5]. In disease states, other regulatory molecules have also
been identified that may have an important role in regulating
energy homeostasis. One such molecule is MIC-1/GDF15 [6], an
unusual and divergent member of the TGF-b superfamily,
sometimes known as GDF15, PLAB, NAG-1 or PTGFB [6–8].
We have previously demonstrated that this cytokine is an
important cause of the anorexia/cachexia of cancer [9].
Many patients with different types of cancers have elevated
circulating levels of MIC-1/GDF15 [10–13]. Serum MIC-1/
GDF15 levels can rise dramatically in advanced cancer, from the
normal mean of about 450 pg/ml to up to 10,000–100,000 pg/ml
[8,10]. MIC-1/GDF15 levels of above 5,000–8,000 pg/ml cause
severe anorexia/cachexia [9], and animal studies demonstrate that
this is likely due to direct actions of MIC-1/GDF15 on feeding
centres in the brainstem and hypothalamus [9]. In addition,
elevated serum MIC-1/GDF15 levels have also been linked to
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cachexia associated with chronic renal [9] and cardiac failure
[14,15]. Lastly, as we have previously reported, a mouse model
with transgenic overexpression of MIC-1/GDF15 also displayed
decreased body weight and fat mass, in association with a decrease
in food intake [16]. While these data demonstrated a clear causal
link between markedly elevated MIC-1/GDF15 serum levels and
MIC-1/GDF15 in mediating changes in energy intake and storage
leading to cachectic syndromes, the role of physiological circulat-
ing levels of MIC-1/GDF15 in energy homeostasis is unknown.
To start addressing the biological actions of physiological
concentrations of MIC-1, we compared body composition and
food intake between MIC-1/GDF15 deficient (MIC-12/2) mice
and syngeneic wildtype (MIC-1+/+) mice. We also analysed
possible differences in metabolic activity by comparing respiratory
exchange ratio, energy expenditure and physical activity between
genotypes. Lastly, we infused MIC-12/2 and MIC-1+/+mice with
human MIC-1/GDF15 to increase circulating MIC-1/GDF15
concentrations to various levels within the physiological range in
order to evaluate the effects on body weight and appetite. These
studies demonstrate that MIC-1/GDF15 is likely to play a role in
the physiological regulation of energy intake and expenditure.
Materials and Methods
All procedures were approved and performed in accordance
with the guidelines of the Garvan Institute and St. Vincent’s
Hospital Animal Experimentation Ethics Committee (AEC 11/
36). All animals were maintained under a controlled temperature
of 22uC and a 12-h dark and 12-h light cycle. Mice were given ad
libitum access to standard rodent chow (Gordon’s Specialty Stock
Feeds, Yanderra, NSW, Australia) and water.
Generation of MIC-12/2 Mice
Mice with germline-deleted MIC-1/GDF15 (MIC-12/2) was
generated by Ozgene (Ozgene Pty Ltd., Bentley DC, WA
Australia). These mice have a complete deletion of the second of
two exons of the MIC-1/GDF15 gene. This effectively deleted the
poly A tract and amino acids 94–302 of MIC-1/GDF15, including
all of the mature bioactive domain and most of the propeptide
region. The founder mice were bred for more than 10 generations
onto a C57BL/6 background.
MIC-1/GDF15 Reagents
All MIC-1/GDF15 antibodies and recombinant protein were
prepared as previously described [17]. Briefly, recombinant
human MIC-1/GDF15 was expressed and purified to homoge-
neity from conditioned medium of the yeast Pichia pastoris that is
free from LPS. The monoclonal antibody against human MIC1/
GDF15 (mAb-26) was purified by protein G affinity chromatog-
raphy.
Figure 1. MIC-12/2 are heavier than MIC-1+/+ mice. (A) Male and (B) female MIC-12/2 mice and syngeneic control MIC-1+/+ mice were weighed
once every four weeks from age of 4 weeks to 1 year. Both male and female MIC-12/2 mice were on average 6–10% heavier than the MIC-1+/+ mice
(male n=13/group, p=0.04; female n=13/group, p=0.01 repeated measures ANOVA). The weight difference between genotypes appeared from the
age of 4 weeks with increased weight differences with ageing in both (C) male and (D) female mice (male n= 13/group, p=0.044, r2=0.32; female
n= 13/group p,0.001, r2= 0.55, linear regression). Data expressed as mean 6 SE.
doi:10.1371/journal.pone.0055174.g001
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Indirect Calorimetry
Indirect calorimetry was performed in age matched mice at 12–
16 weeks of age using an eight-chamber open-circuit calorimeter
(Oxymax Series; Columbus Instruments, Columbus, OH, USA).
Mice were weighed and singly housed in Plexiglass cages
(20.1610.1612.7 cm) and were left to acclimatized for 24 h
before commencement of 48 h-recordings. Oxygen consumption
(Vo2) and carbon dioxide (Vco2) were measured every 15 min.
The respiratory exchange ratio (RER) was calculated as the
quotient of Vco2/Vo2, with an RER of 1 indicating 100%
carbohydrate oxidation and an RER of 0.7 indicating 100% fat
oxidation [18]. Energy expenditure was measured as production of
kcal of heat and was calculated as Calorific Value (CV) 6 Vo2,
where CV is 3.815+1.232 6 RER [19]. Data for the 24-h
monitoring period was averaged for 1-h intervals for RER and
energy expenditure (kcal/h). Ambulatory activity was recorded
with an OPTO-M3 infrared beam sensor system (Columbus
Instruments, Columbus, OH). The senor beams were aligned on
both x and y-axes directions. Data was collected at 1 min intervals
at the same time as the indirect calorimetry measurements. The
recording of ambulatory activity (locomotion) only counts the
broken beam when a consecutive adjacent beam is broken, and
does not include the same beam being broken repeatedly [20].
The total counts of x and y-axes for every 1-h interval from
individual mouse were used for analysis of ambulatory activity.
Measurement of Body Composition
Whole body fat mass and lean mass were measured in MIC-12/
2 and control mice at 12–14 weeks of age. Animals were subjected
to dual-energy X-ray absorptiometry (DXA; PIXImus2 mouse
densitometer; GE Health-care, Waukesha, WI) after anesthetized
with isoflurane. The head and the tail were excluded from all the
measurements.
Tissue Collection
Upon completion of metabolic and body composition measure-
ments, mice at 14–16 weeks of age were sacrificed by cervical
dislocation. Muscles (gastrocnemius and tibialis), whole interscap-
ular brown adipose tissue, as well as white adipose tissue depots
(inguinal, epididymal, mesenteric and retroperitoneal) were
collected and weighed. Total white adipose tissue (WATt) mass
is defined as the sum of the mass of these four WAT depots.
Subcutaneous Osmotic Pump Implantation
Recombinant human MIC-1/GDF15 was reconstituted in
4 mM HCl and loaded into a 7-day-Mini-osmotic pump (model
1007D, ALZET Osmotic pump, Cupertino, CA) to deliver 1 ug/
24 h/20 gBW at delivery rate of 0.5 ul/h. MIC-1/GDF15 or
vehicle-loaded pumps were implanted subcutaneously in the
interscapular region of 10–14 week-old MIC-12/2 or MIC-1+/+
mice. Briefly, animals were anesthetized by inhalation of isoflurane
then shaved and disinfected over the implantation site. A small
incision was made across the midline and slightly posterior to the
Figure 2. Lack of MIC-1 signaling alters the regulation of body fat depots. (A) Whole body lean mass and (B) fat mass was determined by
dual energy X-ray absorptiometry (DXA) in 15 mice per group at 12–14 weeks of age. Female MIC-12/2 mice had lower lean mass relative to control
mice (p,0.01, n= 15/group, t-test), Both male and female MIC-12/2mice had significantly higher fat depot mases compared to synergic control (male
p,0.01, female p= 0.04, n= 15/group, t-test). Mass of individual white adipose tissue depots were measured in (C) male and (D) female mice (n= 9/
group) aged between 14–16 weeks. Fat masses, namely inguinal, epididymal (Epididy), mesenteric (Mesent), retroperitoneal (Retrop), and total white
adipose tissue (WATt) were normalized to body weight. In both male and female MIC-12/2 mice, WATt depots were significantly higher than the
synergic control (male p,0.01, female p= 0.02, n= 9/group, t-test). Data are means 6 SE. Significance indicated as ( ) for p,0.05 or ( ) for p,0.01.
doi:10.1371/journal.pone.0055174.g002
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scapula, then a hemostat was used for blunt dissection into the
subcutaneous space to create a space for the pump, which was
inserted with the delivery portal oriented caudally. The wound was
closed with two 9 mm wound clips. Mice were sacrificed at either
day 5 or 6 after implantation for blood collection.
Body Weight and Food Intake Study
Mice were transferred from group house on soft bedding to
individual cages with paper-towel and allowed to acclimatize for
three days before commencement of food intake measurements.
Body weight, food spillage on the bedding and food in the food
hopper were weighed at between 9:00 and 10:00 h. Food
consumption was calculated using the weight of food pellets left
in the hopper as well as the weight of food (minus feces) spilled on
the bedding [9].
Quantification of Serum MIC-1/GDF15 Levels in Mice
Mice were sacrificed at day 6 after implantation of osmotic
minipump. Blood samples were collected by cardiac puncture and
allowed to clot by standing for 2 hour at 4uC. After centrifugation,
the collected sera were stored at 270uC for assay of human MIC-
1/GDF15 by a previously described, in house ELISA [21,22].
Statistical Analysis
The difference in body weight between the MIC-12/2 and
MIC-1+/+ animal over 52 weeks were average of 12 animals in
each group for each age. Comparison of energy expenditure
between genotypes were performed first by determining the
equality of variance between the group with Levene’s test followed
by ANCOVA with lean body mass as covariate, which also tested
the homogeneity of regression line slopes between the groups
(SPSS version 20, Chicago, IL). All data for energy expenditure
were readjusted at a common lean mass generated by ANOVA
and subsequent comparison between the groups was performed
using repeated-measure ANOVA or t-test. RER and physical
activity collected over 24-h were averaged for the whole 24-h
period, as well as for the light and dark phase, comparison
between genotypes within the same sex or between difference
treatments were performed using an repeated measures ANOVA
and unpaired-two-tailed t-test or with when values over different
times were analyzed. These analyses were performed using
GraphPad Prism (PRISM 4, GraphPad, San Diago, CA).
Equation of Power analysis was used for determining animal
number required for 95% power and 5% significance in food
intake between male genotypes, which was derived by using the
standard deviation and difference between mean in food intake of
genotypes [23].
Figure 3. Female MIC-12/2 mice eat more. (A) Spontaneous 3 day cumulated food intake was measured in male and female MIC-12/2 and
control mice at 13 weeks of age. All mice were fed with standard chow diet ad libitum. Similar food intake was observed between male genotypes
(p= 0.3, n= 8/group, t-test), female MIC-12/2 mice had higher food intake relatively to the control mice (p= 0.05, n= 8/group). (B) Cumulated 24-hour
fasting-induced food intake of was performed with the same group of mice at age of 14 weeks. MIC-12/2 and control mice were fasted for 24 hours
before re-introduction of food and spillage were collected at indicated time points, no genotypic difference were observed both male and female
mice. Food intake at (C) light and (D) dark phase was also measured in the same group of mice at age of 12 weeks. No significant changes were
observed between MIC-12/2 and control mice in both sexes. Data are normalized to body weight plotted as means 6 SE. Significance indicated as
( ) for p#0.05.
doi:10.1371/journal.pone.0055174.g003
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Results
MIC-12/2Mice have Increased Body Weight and Fat Mass
To investigate whether MIC-1/GDF15 might contribute to the
physiological regulation of energy homeostasis, the body weight of
MIC-12/2 mice and syngeneic controls were monitored between
the ages of 4 weeks to 1 year. Male MIC-12/2 mice were on
average 660.6% heavier than male MIC-1+/+ control mice of the
same age, and female MIC-12/2 mice weighed on average
1060.7% more than female controls (Fig. 1A and 1B, male
p=0.04; female p=0.01). For both male and female mice, the
weight differences between genotypes increased significantly over
time (Fig. 1C and 1D, female p,0.01; male p=0.04).
To understand what might have contributed to the increased
body weight in MIC-12/2 mice, whole body lean and fat mass
were determined by dual energy X-ray absorptiometry (DXA).
Whilst male MIC-12/2 mice show a similar lean body mass to age
and sex matched controls, female MIC-12/2 mice had a
significantly lower lean body mass than age and sex matched
MIC-1+/+ mice (Fig. 2A, male p=0.21; female p,0.01). Both male
and female MIC-12/2 mice had a significantly higher total fat
mass relative to the sex matched MIC-1+/+ mice (Fig. 2B, male
p,0.01; female p=0.04).
To further delineate differences in body composition, tissue
specific lean mass and fat depot weights were measured directly.
There was no significant difference between MIC-1+/+ and MIC-
12/2 mice of either sex in the relative mass of either the
gastrocnemius or tibialis muscles (data not shown), and no
differences were observed in mass of brown adipose tissue
(Fig. 2C, 2D, male p=0.35, female p=0.35). However, there
was a significant increase in total white adipose tissue mass
(WATt), normalized to body weight, in both male and female
MIC-12/2 animals (Fig. 2C, 2D, male p,0.01, female p = 0.02).
This was associated with marked significant increases in the weight
of the inguinal, mesenteric and/or retroperitoneal fat depots in
MIC-12/2 compared to control mice (Fig. 2C, 2D). These data
indicate that MIC-1/GDF15 plays a role in regulating body
composition and energy storage in mice.
Female but not Male MIC-12/2 Mice have Increased
Spontaneous Food Intake
To examine possible causes for the increased body weight and
fat mass in the MIC-12/2 mice, we first studied their spontaneous
Figure 4. Male MIC2/2 mice exhibit similar metabolic activity to their synergic control mice. Metabolic activity of male MIC-12/2 and
control mice with groups of 16 at age between 14–16 weeks was determined by time course of (A) respiratory exchange rate (RER), (B) energy
expenditure and (C) ambulatory activity. Energy expenditure was adjusted for lean mass via ANCOVA (common lean mass = 25.65 g). (D) Energy
expenditure and (E) ambulatory activity were also presented as total for 24 hour, light phase and dark phase. Data are normalized to body weight and
plotted as means 6 SE.
doi:10.1371/journal.pone.0055174.g004
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food intake. Female but not male MIC-12/2 had significant
increased food intake compared to the age and sex-matched
control mice, both in absolute terms (15.5960.67 versus
12.7760.88 g/gBW/d in female knockout and control mice,
respectively) and when normalized to body weight (p = 0.05 for
female mice (Fig. 3A). This data suggested that the increased body
weight in female MIC-12/2 is at least partly due to increased food
intake. Whilst the 3.7% difference in food intake between male
MIC-12/2 and MIC-1+/+ was not statistically significant, this may
reflect the capacity of our method to detect small differences in
food intake. Power analysis indicates that to determine with 95%
certainty whether this 3.7% difference in food intake was
significant would require 126 mice of each genotype. As, over a
more prolonged period, a difference in 3 days-accumulated food
intake of as little as 3.7% is likely to be able alter body weight and
composition [23], in this study, we cannot exclude such a small
difference being present.
As the timing of food intake can influence energy storage
independently of total intake [24], we also measured food intake
after fasting, as well as during the light and dark phases in all
animals (Figs 3B, 3C, 3D). However, there was no difference
between knockout and control mice of either sex with respect to
re-feeding after a 24-hour fast (Fig. 3B, p = 0.8 for both sexes).
Additionally, there were no significant differences in the pattern of
food intake in the light and dark phase between male and female
MIC-12/2 and control mice (Fig. 3C, 3D).
Female but not Male MIC-12/2 Mice have Lower Total
Energy Expenditure
To further investigate possible mechanisms underlying the
increases in body weight and adiposity of male and female MIC-
12/2 versus MIC-1+/+ mice, we compared their respiratory
exchange ratio (RER), energy expenditure and physical activity
(Figs 4 and 5). The increased body weight and adiposity of MIC-
12/2 animals does not appear to result from differential use of
lipids versus carbohydrate as oxidative fuel sources as there was no
difference in RER between genotypes (Fig. 4A, 5A). Female mice,
MIC-12/2 animals exhibit significantly lower energy expenditure
Figure 5. Female MIC2/2 mice exhibit lower metabolic activity than their synergic controls. Metabolic activity of female MIC-12/2 and
control mice with groups of 9 at age between 14–16 weeks was determined by time course of (A) respiratory exchange rate (RER), (B) energy
expenditure and (C) ambulatory activity. Energy expenditure (EE) was adjusted for lean mass via ANCOVA (common lean mass = 18.72 g), EE were
significantly lower measured over 24 hour in MIC-12/2 mice (p= 0.001, n= 9/group, repeated measures ANOVA). (D) MIC-12/2 also displayed lower
total EE in time courses over 24 hour, light phase and dark phase (p= 0.001. p= 0.005 and p,0.001, respectively, n= 9/group, t-test). (E) Physical
activity in dark phase were significantly lower in MIC-12/2 mice (p= 0.03, n= 9, t-test). Data are normalized to body weight and plotted as means 6
SE. Significance indicated as ( ) for p,0.05 or ( ) for p,0.01, or ( ) for p,0.001.
doi:10.1371/journal.pone.0055174.g005
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Figure 6. Major contribution to genotypic difference in total EE was basal metabolism. Correlation between physical activity and EE was
based on average values collected over 24 h. Each point represents data collected in 1-h intervals from the (A) male MIC-12/2 and control mice
(Trend line equation: MIC-12/2 y= 12932x –4375 R2= 0.8705, control y=18893x –6637 R2=0.8813) and (B) female MIC-12/2 and control mice (Trend
line equation: MIC-12/2 y= 18517x –6851 R2= 0.8796, control y= 12326x –3628 R2=0.8261). Basal metabolic rate is determined using the function
from the trend line and extrapolating to set the physical activity to zero. No significant difference in basal metabolic rate between the male
genotypes (0.3560.01 vs 0.3460.02, respectively, p=0.23, n= 15/group). Basal metabolic rate was significantly lower in the female MIC-12/2 mice
compared to control (0.3760.02 vs 0.2960.01, respectively, p,0.01, n= 9/group). Data are means 6 SE.
doi:10.1371/journal.pone.0055174.g006
Figure 7. Physiological levels of human MIC-1/GDF15 reduce weight and food intake in mice. Male MIC-12/2 and MIC-1+/+ mice were
infused with human MIC-1/GDF15 (1ug/20gBW/d) or vehicle via osmotic mini-pump. Food intake, body weight and serum levels of human MIC-1/
GDF15 were measured on day 5 of infusion. (A) MIC-1/GDF15-treated MIC-12/2 mice had an average serum MIC-1/GDF15 level of 643667 pg/ml and
weighed 95.8660.77% of their starting body weight whilst vehicle-treated mice weighed 102.360.75% of their starting weight (n= 6/group, p,0.01
unpaired t-test). (B) MIC-1/GDF15-treated MIC-1+/+ mice had an average serum MIC-1/GDF15 level of 576645 pg/ml and weighed 99.8660.47% of
their starting weight whilst vehicle-treated mice weighed 10260.52% (n= 14, p=0.01 unpaired t-test). This decreased body weight in both genotypes
was associated with reduced food intake. (C) MIC-1/GDF15-treated MIC-12/2 and (D) MIC-1/GDF15-treated MIC-1+/+ consumed significantly less food
than the matched vehicle-treated mice of same genotype (MIC-12/2 n= 6/group, p= 0.04; MIC-1+/+ n=14/group, p,0.01 unpaired t-test). Data
expressed as mean 6 SE.
doi:10.1371/journal.pone.0055174.g007
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normalized to bodyweight compared to the age matched control
MIC-1+/+ mice (p,0.01, Fig. 5B, 5D). This difference may be
partially attributed to a decrease in physical activity, since physical
activity was significantly decreased during the dark phase in female
MIC-12/2 versus control mice (p = 0.03, Fig. 5C, 5E). No such
differences in energy expenditure or physical activity were
observed between MIC-12/2 and MIC-1+/+ male mice (Fig. 4B,
4C, 4D, 4E).
To determine the likely contribution of changes in physical
activity to changes in energy expenditure, correlation analysis was
performed using hourly data from individual mice. There was a
positive correlation between energy expenditure and physical
activity within all the groups (p,0.02 by Pearson correlation for all
groups, Fig. 6A and 6B). In both males and females, the difference
in the slope of the regression line is significantly different for MIC-
12/2 and MIC-1+/+ mice (p,0.01 in all group, Fig. 6), indicating
that the energy cost of activity was different between genotypes.
Further, to estimate basal metabolic rate, the function from the
trend line was used to extrapolate physical activity to zero, with the
point at which the line crosses the X-axis signifying basal
metabolic rate. While there was no genotypic difference in basal
metabolic rate between males (Fig. 6A), female MIC-12/2
displayed a significantly lower basal metabolic rate compared to
wild type controls (p,0.01) (Fig. 6B). These data indicate that
there is a fundamental metabolic difference between the male and
female MIC-12/2 mice relatively to their matched controls,
suggesting MIC-1/GDF15 exerts its effects differentially on male
and female mice. The difference in total energy expenditure
between the female genotypic groups may have been more
affected by changes in basal metabolic rate and less by the physical
activity. Both of these are likely to contribute to the body weight
difference displayed in female MIC-12/2 versus control mice.
MIC-1/GDF15 Reduces Food Intake and Induces Weight
Loss in MIC-12/2 and MIC-1+/+ Mice
To investigate whether the increased body weight of MIC-12/2
mice was specifically due to germline gene deletion of MIC-1/
GDF15 and not resulting from any unrecognized compensatory or
developmental changes in MIC-12/2 mice, we continuously
infused male MIC-12/2 and MIC+/+ mice with MIC-1/GDF15
(1–2 mg/d) via osmotic minipumps. Infusion of MIC-1/GDF15
over 5 days resulted in increased circulating human MIC-1/
GDF15 levels from zero to 643667 pg/ml and 576645 pg/ml in
MIC-12/2 and MIC-1+/+ mice, respectively. As discussed below,
this would have the effect of increasing total MIC-1/GDF15 levels
in MIC-12/2 mice to about the middle of the human normal
range and in MIC-1+/+ mice to the top of the human normal
range. This infusion of MIC-1/GDF15 resulted in reduced body
weight gain relative to syngeneic vehicle-infused controls (Fig. 7A
and 7B, MIC-12/2 p,0.01; MIC-1+/+ p=0.01), coupled with a
significant reduction in food intake (Fig. 7C and 7D, MIC-12/2
p=0.04; MIC-1+/+ p,0.01).
Discussion
In addition to high circulating levels of MIC-1/GDF15
mediating anorexia/cachexia in disease states [9], this study
demonstrates that changes in MIC-1/GDF15 in the physiological
range modifies feeding behavior and body weight in mice. The
physiological range of MIC-1/GDF15 in mouse blood is currently
unknown due to the lack of any immunoassay for, or monoclonal
antibody to murine MIC-1/GDF15. Taken that the normal range
for MIC-1/GDF15 in human serum is 150–1150 pg/ml [8] and
assuming MIC-1/GDF15 serum levels are similar in humans and
in mice, this means that the level of human MIC-1/GDF15
introduced in MIC-12/2 and MIC-1+/+ mice was at middle or the
upper limit of the normal human physiological range, respectively.
Since this resulted in decreased body weight and food intake in
both groups relatively to its control, it indicates that receptor
upregulation or developmental changes in MIC-12/2 mice are
not responsible for human MIC-1/GDF15-induced changes in
food intake and body weight, suggesting that there is a specific
physiological role of MIC-1/GDF in regulation of energy intake,
storage and expenditure.
Although there were distinct differences between male and
female mice that are discussed below, in general MIC-1/GDF15
deficient mice exhibited increased body weight, adiposity and – in
female mice – food intake. This phenotype was associated with a
decrease in physical activity and basal metabolic energy expen-
diture in female animals. These changes in food intake and body
weight in male and female mice were due to lack of serum MIC-1/
GDF15 in the knockout animals, since administration of
physiologically relevant amounts of human MIC-1/GDF15
decreased food intake and body weight in both MIC-12/2 and
syngeneic MIC-1+/+ mice.
Despite having a similar phenotype with respect to increased
body weight and adiposity, the effects of MIC-1/GDF15 gene
deletion was greater in female than in male mice and the
underlying physical/metabolic changes differed between the sexes
in some aspects. This suggests that MIC-1/GDF15 exert its effect
differentially between male and female animals. This is consistent
with epidemiological data from human cohorts, where there are
sex-related differences in the relationship between MIC-1/GDF15
and anthropometric measurements (e.g. waist-to-hip ratio) [25,26].
In mice, female but not male MIC-12/2 mice displayed a
significant reduction in lean mass, a significant increase in
spontaneous food intake as well as significantly reduced energy
expenditure, basal metabolic rate and physical activity compared
to control mice. Although white adipose tissue consumes/stores
energy and helps to regulate metabolic rate, lean mass consumes
much more energy than the fat mass [27,28]. Therefore, the
relatively reduced lean mass seen only in the female MIC-12/2
female mice may have contributed to the associated reduction in
energy expenditure and basal metabolic rate in these animals, and
may help to explain the greater difference in body weight of the
female MIC-12/2 versus control mice.
Whilst male mice MIC-12/2 weight more, and are more obese
than their syngeic controls, this difference is less than in females
and its aetiology is less clear. The increase in spontaneous food
intake in male MIC-12/2 mice was not statistically significant,
either because no real difference existed or because the study was
underpowered to detect a small difference. However, it is
noteworthy that in humans, sustained small changes in daily
energy intake, as low as 10 kcal, are capable of altering body
weight and composition [29,30]. Additionally, it is not uncommon
for C57BL5 mice to display changes in body weight and body
composition with little or no changes in energy intake [31].
Like MIC-1/GDF15, various other members of the TGF-b
superfamily are also involved in the regulation of adipogenesis and
energy metabolism by signaling through the smad and p38
mitogen-activated protein kinase (p38MAPK) signaling pathways,
or alternatively signaling through other members of MAPK family
such as ERK and JNK [32]. Whilst the effects are controversial, in
general, bone morphogenetic proteins (BMPs) direct commitment
of preadipocytes to either the white (BMP2 and BMP4) or the
brown adipocyte (BMP7) lineage. [BMP7 also increases mito-
chondrial biogenesis leading to increased energy expenditure
[27,33–36]. By contrast, TGF-b1 and activin inhibit the differen-
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tiation of preadipocytes to mature adipocytes and hamper lipid
accumulation [37–39]. Additionally, in mouse knockout models,
growth differentiation factor 3 (GDF3) deficient mice displayed
increased basal metabolic rate, and myostatin deficient mice
displayed decreased skeletal muscle mass with increased adiposity
[40–42], which contrasted to what female MIC-12/2 exhibited,
suggesting a novel role of MIC-1/GDF15 in the regulation of
metabolic rate and possibly also myogenesis. Both male and
female MIC-12/2 mice have increased white but no alteration in
brown adipose tissue mass. This could indicate a possible role for
MIC-1/GDF15 in inhibition of lipid formation and/or accumu-
lation. However the increase in adiposity MIC-12/2 mice is more
likely to have developed because of increase in food intake, at least
in female mice. Whilst in male mice, we could not identify
significant alteration in food intake, small differences, significant
enough to alter body weight and compositions could still exist but
are beyond our capacity to detect in this study.
MIC-1/GDF15 was first identified as an appetite regulator
when it was discovered that its overexpression in cancer and other
diseases lead to anorexia/cachexia. The data in this study
indicates that under physiological conditions, MIC-1/GDF15 also
plays a small role in the regulation of energy intake and
expenditure, with greater effects in females than in males. Thus
it would appear that diseases associated with marked increases in
MIC-1/GDF15 expression subvert a normal physiological path-
way to cause anorexia/cachexia. A better understanding of this
pathway is important for a complete understanding of energy
homeostasis and more effective therapy of the anorexia/cachexia
syndrome.
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